<DOC>
	<DOCNO>NCT01588626</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics AZD6140 active metabolite , safety , tolerability AZD6140 follow single administration healthy male Japanese volunteer .</brief_summary>
	<brief_title>Study Assess Pharmacokinetics AZD6140 After Single Dose Healthy Japanese Male Volunteers</brief_title>
	<detailed_description>A Phase I , Single Centre , Open Study Assess Pharmacokinetics oral AZD6140 Single Dose Healthy Japanese Male Volunteers</detailed_description>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Healthy male subject age 20 45 year inclusive Body mass index ( BMI=weight/height2 ) 18.0 27.0 kg/m2 inclusive Body weight 50.0 85.0 kg inclusive Provision write informed consent Clinically significant abnormality clinical chemistry , haematology urinalysis result judge investigator , positive result screen test serum hepatitis B surface antigen hepatitis C antibody , syphilis human immu Supine blood pressure &gt; 150 mmHg systolic &gt; 95 mmHg diastolic supine pulse &gt; 90 beat per minute ( rest 10 minute ) Personal family history bleeding disorder , reasonable suspicion vascular malformation , include aneurysms Personal familial predisposition thrombotic disorder Clinically significant medical history , include psychiatric disorder severe allergy</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>Japanese male</keyword>
	<keyword>PK study</keyword>
</DOC>